Protalix jumps on exploration of strategic alternatives

Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX) jumped $0.79 (15%) to $6.15 on Tuesday after announcing that it engaged Citigroup to assist in exploring strategic alternatives including product partnering and technology sharing. At Sept. 30, 2012, Protalix had $50.2 million in cash and a nine-month operating loss of $2 million. ...